Summary of clinical responses at enrollment and after Bor-HDM
| Response . | After induction therapy . | After ASCT with Bor-HDM . | ||||||
|---|---|---|---|---|---|---|---|---|
| All patients (n = 54) . | VAD (n = 29) . | Bor/Dex (n = 1)8 . | 2 or more lines (n = 7) . | All patients (n = 53)* . | VAD (n = 28)* . | Bor/Dex (n = 18) . | 2 or more lines (n = 7) . | |
| CR | 2 (4) | 0 | 2 (11) | 0 | 17 (32) | 9 (32) | 7 (39) | 1 (14) |
| VGPR | 15 (28) | 6 (21) | 8 (44) | 1 (14) | 20 (38)† | 10 (36) | 6 (33) | 4 (57) |
| PR | 31 (57) | 20 (69) | 5 (28) | 6 (86) | 13 (24) | 7 (25) | 5 (28) | 1 (14) |
| SD | 6 (11) | 3 (10) | 3 (17) | 0 | 2 (4) | 2 (7) | 0 | 0 |
| PD | 0 | 0 | 0 | 0 | 1 (2) | 0 | 0 | 1 (14) |
| CR + VGPR | 17 (32) | 6 (21) | 10 (55) | 1 (14) | 37 (70) | 19 (68) | 13 (72) | 5 (71) |
| Response . | After induction therapy . | After ASCT with Bor-HDM . | ||||||
|---|---|---|---|---|---|---|---|---|
| All patients (n = 54) . | VAD (n = 29) . | Bor/Dex (n = 1)8 . | 2 or more lines (n = 7) . | All patients (n = 53)* . | VAD (n = 28)* . | Bor/Dex (n = 18) . | 2 or more lines (n = 7) . | |
| CR | 2 (4) | 0 | 2 (11) | 0 | 17 (32) | 9 (32) | 7 (39) | 1 (14) |
| VGPR | 15 (28) | 6 (21) | 8 (44) | 1 (14) | 20 (38)† | 10 (36) | 6 (33) | 4 (57) |
| PR | 31 (57) | 20 (69) | 5 (28) | 6 (86) | 13 (24) | 7 (25) | 5 (28) | 1 (14) |
| SD | 6 (11) | 3 (10) | 3 (17) | 0 | 2 (4) | 2 (7) | 0 | 0 |
| PD | 0 | 0 | 0 | 0 | 1 (2) | 0 | 0 | 1 (14) |
| CR + VGPR | 17 (32) | 6 (21) | 10 (55) | 1 (14) | 37 (70) | 19 (68) | 13 (72) | 5 (71) |
Values are number (%) of patients.
Bor-HDM indicates bortezomib and high-dose melphalan, ASCT, autologous stem cell transplantation; VAD, vincristine, Adriamycin, and dexamethasone; Bor/Dex, bortezomib and dexamethasone; CR, complete response; VGPR, very good partial response; PR, partial response; SD, stable disease; and PD, progressive disease.
One patient, who was in PR after VAD induction therapy, did not receive the planned ASCT because of pulmonary aspergillosis.
Three patients with negative immunofixation but without bone marrow evaluation were assessed as VGPR.